Practicability and acceptance of subcutaneous self-administration of the selective serotonin agonist sumatriptan

Headache

Volumn 38, Issue 4, 1998, Pages 267-269

  Göbel, Hartmut ^a,b   Baar, H ^a   Beikufner H D ^a   Bohme K ^a   Beckmann Reinhold, A ^a  

^a UNIVERSITY OF KIEL   (Germany)

^b NONE   (Germany)

Author keywords

Autoinjector; Glaxo Pen; Migraine; Subcutaneous; Sumatriptan; Therapy

Indexed keywords

SEROTONIN AGONIST; SUMATRIPTAN;

ARTICLE; ASTHENIA; CLINICAL TRIAL; DRUG BIOAVAILABILITY; DRUG SELF ADMINISTRATION; GERMANY; HEADACHE; HEART PALPITATION; HEMATOMA; HUMAN; MAJOR CLINICAL STUDY; MALAISE; MIGRAINE; MULTICENTER STUDY; NAUSEA; PARESTHESIA; PATIENT SATISFACTION; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION; TASTE DISORDER; THORAX PAIN;

EID: 2642612808     PISSN: 00178748     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1526-4610.1998.3804267.x     Document Type: Article

References (16)

1. Lloyd K. The clinical profile of sumatriptan: safety and tolerability. Eur Neurol. 1994;34(suppl 2):40-43.
2. Peroutka SJ. Sumatriptan in acute migraine: pharmacology and review of world experience. Headache. 1990;30(suppl 2):554-560.
3. Pilgrim AJ. The clinical profile of sumatriptan: efficacy in migraine. Eur Neurol. 1994;34(suppl 2):26-34.
4. Tfelt-Hansen P. Sumatriptan for the treatment of migraine attacks - a review of controlled clinical trials. Cephalalgia. 1993;13:238-244.
5. Gross ML, Kay J, Turner AM, Hallett K, Cleal AL, Hassani H. Sumatriptan in acute migraine using a novel cartridge system self-injector. United Kingdom Study Group. Headache. 1994;34:559-563.
6. Gross ML, Kay J, Turner AM, Jewsbury J, Cleal AL. Long-term efficacy of subcutaneous sumatriptan using a novel self-injector. Headache. 1995:35:601-606.
7. Göbel H, Stolze H, Heinze A, et al. Achtzehnmonatige langzeitanalyse der Wirksamkeit, Sicherheit und vertraglichkeit von sumatriptan s.c. in der akut therapie von migraneanfallen. Nervenarzt. 1996;67:471-483.
8. Schoenen J, Bulcke J, Caekebeke J, et al. Self-treatment of acute migraine with subcutaneous sumatriptan using an auto-injector device: comparison with customary treatment in an open, longitudinal study. Cephalalgia. 1994;14:55-63.
9. Headache Classification Committee of the International Headache Society. Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Cephalalgia. 1988;8(suppl 7):1-96.
10. Dahlof C, Ekbom K, Persson L. Clinical experiences from Sweden on the use of subcutaneously administered sumatriptan in migraine and cluster headache. Arch Neurol. 1994;51:1256-1261.
11. Ensink FB. Subcutaneous sumatriptan in the acute treatment of migraine. Sumatriptan International Study Group. J Neurol. 1991;238(suppl 1):S66-S69.
12. Göbel H. Der aktuelle Stellenwert von sumatriptan in der therapie des migraneanfalles. Nervenheilkunde. 1994;13:239-252.
13. Göbel H. Die Kopfschmerzen. Ursachen, Mechanismen, Diagnostik und Therapie in der Praxis. Lehrbuch. New York: Springer Verlag; 1996:1-901.
14. Göbel H, Krapat S, Ensink FB, Soyka D. Comparison of contingent negative variation between migraine interval and migraine attack before and after treatment with sumatriptan. Headache. 1993;33:570-572.
15. Göbel H, Krapat S, Dworschak M, Ensink FB, Soyka D. Exteroceptive suppression of temporalis muscle activity during migraine attack and migraine interval before and after treatment with sumatriptan. Cephalalgia. 1994; 14: 143-148.
16. Tansey MJ, Pilgrim AJ, Martin PM. Long-term experience with sumatriptan in the treatment of migraine. Eur Neurol. 1993:33:310-315.